Shane Arnold

With deep expertise in rare neuro-oncology and a strong track record in global medical affairs, I bring a science-driven, strategic mindset to advancing innovative therapies from development to launch. As the Global Program Team (GPT) medical asset lead for the Neurofibromatosis 1 (NF1) program, I’ve driven cross-functional initiatives to accelerate impact—from building comprehensive evidence generation plans to shaping global launch strategies.

My experience spans managing robust portfolios of externally sponsored research, building key partnerships with leading institutions like the NCI, and co-authoring Target Product Profiles that align with evolving regulatory and commercial needs. I thrive at the intersection of science and strategy—contributing medical expertise to development programs, supporting business development opportunities, and aligning global teams behind shared objectives.

Whether co-leading alliance initiatives with top biopharma partners or presenting strategic plans to executive leadership, I’m committed to delivering patient-centric, evidence-based impact on a global scale.

Let’s connect if you’re passionate about advancing science, driving innovation in rare diseases, or exploring collaborative opportunities in global medical affairs.

Certificates- Harvard Medical School- Cambridge, MA (2020) • Pharmacology and Genetics MBA- Collat School of Business- Birmingham, AL (2008) • Technology Commercialization Research Trainee Fellowship- The Johns Hopkins University School of Medicine - Baltimore, MD (2000) • Biological Chemistry PhD- The University of Alabama at Birmingham – Birmingham, AL (2000) • Biochemistry and Molecular Genetics BS- Tulane University- New Orleans, LA (1993) • Cell and Molecular Biology